EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial
1. ENGN stock rose 64.73% to $9.90 on high trading volume. 2. Preliminary data shows 63% complete response rate in bladder cancer trial. 3. Company surpassed patient enrollment target by 25% for LEGEND trial. 4. BLA filing expected in late 2026, with potential FDA approval in 2027. 5. CEO expresses optimism regarding commercial potential of detalimogene.